CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting rare inherited diseases involving the liver and genetically defined cancers, today announced financial and operational results for the quarter and full year ended December 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
